|
22 Jan 2020 |
Akcea and Ionis report positive topline Phase 2 results of AKCEA-APOCIII-L Rx
|
|
22 Jan 2020 |
Celularity Announces FDA Clearance of Landmark IND for CYNK-001, an Allogeneic, Off-the-Shelf Cryopreserved NK Cell Therapy
|
|
22 Jan 2020 |
Targovax Announces Encouraging Data in Mesothelioma Study Combining ONCOS-102 and Standard of Care Chemotherapy
|
|
22 Jan 2020 |
PDC*line Pharma raises €20 million in Series B financing round
|
|
21 Jan 2020 |
Biotech start-up Seekyo raises €800k with leverage from French Tech Seed Fund
|
|
17 Jan 2020 |
GeneTx and Ultragenyx Announce Investigational New Drug (IND) Application Active for GTX-102 in Patients with Angelman Syndrome
|
|
17 Jan 2020 |
First Patient Dosed with Cellectis’ New Allogeneic UCART123 Product Candidate for Relapsed/Refractory Acute Myeloid Leukemia
|
|
15 Jan 2020 |
Tmunity Announces First Patient Dosed in Phase 1 Clinical Trial with CART-TnMUC1
|
|
15 Jan 2020 |
UK Regulatory Authority Approves Cynata’s Phase 2 Clinical Trial in Critical Limb Ischaemia
|
|
15 Jan 2020 |
NantKwest and ImmunityBio Announce Complete Response in Metastatic Pancreatic Cancer in the First Patient to Receive PD-L1 Tumor-Targeted Natural Killer Cells (PD-L1.t-haNK) Combined with N-803 IL-15 Fusion Protein
|
|
14 Jan 2020 |
Genome & Company announces a clinical trial collaboration and supply agreement with Merck KGaA, Darmstadt, Germany and Pfizer
|
|
13 Jan 2020 |
Allogene Therapeutics and SpringWorks Therapeutics Announce Clinical Collaboration to Evaluate ALLO-715 in Combination with Nirogacestat in Multiple Myeloma
|
|
13 Jan 2020 |
Precision BioSciences Announces FDA Acceptance of IND for PBCAR269A, a BCMA Targeted Genome Edited Allogeneic CAR T Therapy Candidate for Multiple Myeloma
|
|
13 Jan 2020 |
Abeona Therapeutics Initiates Pivotal Phase 3 Clinical Trial Evaluating EB-101 Gene Therapy for Recessive Dystrophic Epidermolysis Bullosa
|
|
13 Jan 2020 |
BioMarin, Pioneer in Phenylketonuria, to Begin Clinical Trial with BMN 307 Gene Therapy
|
|
13 Jan 2020 |
Moderna Builds on Clinical Validation of Systemic Delivery with Two Additional Development Candidates in New Autoimmune Therapeutic Area
|
|
13 Jan 2020 |
Adaptimmune Announces that SPEAR T-cell Platform Delivers Initial Responses in Four Solid Tumor Indications
|
|
12 Jan 2020 |
LogicBio Therapeutics Announces Collaboration with Takeda to Develop New Genome Editing Candidate LB-301 for the Treatment of Crigler-Najjar Syndrome
|
|
12 Jan 2020 |
LogicBio Therapeutics Announces Submission of Investigational New Drug Application (IND) for LB-001 for Methylmalonic Acidemia (MMA) and Highlights Key Corporate Milestones
|
|
12 Jan 2020 |
Announcement of iPSC Derived Gene-modified NK Cell Development Targeting Solid Tumors
|
|
12 Jan 2020 |
PACT Pharma Raises $75M in Oversubscribed Series C Financing to Develop Fully Personalized NeoTCR-T Cell Therapies for Patients with Cancer
|
|
12 Jan 2020 |
Moderna Announces Additional Positive Phase 1 Data from Cytomegalovirus (CMV) Vaccine (mRNA-1647) and First Participant Dosed in Phase 2 Study
|
|
12 Jan 2020 |
Generation Bio Announces $110 Million Series C Financing to Advance Lead Programs for Hemophilia A and PKU
|
|
12 Jan 2020 |
Indapta Therapeutics and Lonza Announce Strategic Partnership to Advance a Next-generation, Off-the-shelf, Allogeneic Immuno-oncology Therapy
|
|
12 Jan 2020 |
Alnylam Initiates Rolling Submission of New Drug Application (NDA) to U.S. Food and Drug Administration (FDA) for Lumasiran for the Treatment of Primary Hyperoxaluria Type 1 (PH1)
|
